Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Eloxx Pharmaceuticals, Inc. | v475709_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Eloxx Pharmaceuticals, Inc. | v475709_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Eloxx Pharmaceuticals, Inc. | v475709_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Eloxx Pharmaceuticals, Inc. | v475709_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Eloxx Pharmaceuticals, Inc. | v475709_ex31-1.htm |
| EX-2.3 - EXHIBIT 2.3 - Eloxx Pharmaceuticals, Inc. | v475709_ex2-3.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Nos. 333-201891,333-178881, 333-177586, 333-167388,
333-157417, 333-140238, 333-104105, 333-187133 and 333-195688) on Form S-8 and (Nos. 333-170140, 333-166277, 333-148779, 333-146691
and 333-138405) on Form S-3 of Sevion Therapeutics, Inc. and Subsidiaries of our report dated October 13, 2017, relating to the
consolidated financial statements appearing in the Annual Report on Form 10-K of Sevion Therapeutics, Inc. and Subsidiaries for
the year ended June 30, 2017. Our report dated October 13, 2017, relating to the consolidated financial statements includes an
explanatory paragraph relating to an uncertainty as to the Company's ability to continue as a going concern.
/s/ RSM US LLP
New York, New York
October 13, 2017